Skip to main content
PLOS One logoLink to PLOS One
. 2023 Aug 4;18(8):e0281858. doi: 10.1371/journal.pone.0281858

A health terminological system for inherited retinal diseases: Content coverage evaluation and a proposed classification

Hamideh Sabbaghi 1,2, Sina Madani 3, Hamid Ahmadieh 4, Narsis Daftarian 5,*, Fatemeh Suri 4, Farid Khorrami 6, Proshat Saviz 7, Mohammad Hasan Shahriari 8, Tahmineh Motevasseli 4, Sahba Fekri 4, Ramin Nourinia 4, Siamak Moradian 4, Abbas Sheikhtaheri 7,*
Editor: Alfred S Lewin9
PMCID: PMC10403057  PMID: 37540684

Abstract

Purpose

To present a classification of inherited retinal diseases (IRDs) and evaluate its content coverage in comparison with common standard terminology systems.

Methods

In this comparative cross-sectional study, a panel of subject matter experts annotated a list of IRDs based on a comprehensive review of the literature. Then, they leveraged clinical terminologies from various reference sets including Unified Medical Language System (UMLS), Online Mendelian Inheritance in Man (OMIM), International Classification of Diseases (ICD-11), Systematized Nomenclature of Medicine (SNOMED-CT) and Orphanet Rare Disease Ontology (ORDO).

Results

Initially, we generated a hierarchical classification of 62 IRD diagnosis concepts in six categories. Subsequently, the classification was extended to 164 IRD diagnoses after adding concepts from various standard terminologies. Finally, 158 concepts were selected to be classified into six categories and genetic subtypes of 412 cases were added to the related concepts. UMLS has the greatest content coverage of 90.51% followed respectively by SNOMED-CT (83.54%), ORDO (81.01%), OMIM (60.76%), and ICD-11 (60.13%). There were 53 IRD concepts (33.54%) that were covered by all five investigated systems. However, 2.53% of the IRD concepts in our classification were not covered by any of the standard terminologies.

Conclusions

This comprehensive classification system was established to organize IRD diseases based on phenotypic and genotypic specifications. It could potentially be used for IRD clinical documentation purposes and could also be considered a preliminary step forward to developing a more robust standard ontology for IRDs or updating available standard terminologies. In comparison, the greatest content coverage of our proposed classification was related to the UMLS Metathesaurus.

Introduction

Inherited retinal diseases (IRDs) consist of various types of hereditary retinal dystrophies that are primarily involving the outer retina and retinal pigment epithelium (RPE) [1, 2]. Considering the progressive nature of IRDs which can lead to decreased vision-related quality of life (VRQoL), accurate diagnosis and identification of the causative gene mutations are important for genetic consulting as well as allocating research-based trials for the evolving therapies such as gene therapy [35]. Therefore, domain-specific ontologies and reference terminology systems are considered important tools that can facilitate documentation and representation of the complex IRD concepts based on their genotype-phenotype distinctions [68].

Clinical classifications and terminology systems are widely used for standardizing patients’ health information at the point of care for different purposes such as clinical, research, reimbursement, and epidemiological purposes [911]. Additionally, terminological systems are essential for structured documentation of patient data in Electronic Health Record (EHR) systems [12]. One of the crucial advantages of these systems is the establishment of a common controlled vocabulary for effective communication by capturing unified medical terms and concepts [13]. Furthermore, such structured contents can be reused for a variety of purposes and represented in many different information systems [1015].

Based on the intended application, different terminological systems are available in the domain of medicine including Unified Medical Language System (UMLS), Online Mendelian Inheritance in Man (OMIM), International Classification of Diseases (e.g., ICD-11), Systematized Nomenclature of Medicine—Clinical Terms (SNOMED-CT) and Orphanet Rare Disease Ontology (ORDO) [16]. Each system has been developed for a particular purpose. For instance, UMLS is widely used for providing a unique code and term linkage between different terminological systems and facilitating mapping schemas that can be used to create and maintain local terminologies [17]. While ICD classifications can be employed for the identification of health trends, mortality and morbidity statistics [18] as well as clinical and health research purposes; OMIM is optimized for the classification of human genes and genetic disorders [19]. Recently, SNOMED-CT has been designated as the terminology of choice for the standardization of complex medical concepts, such as IRDs, at the point of care [20]. Additionally, Orphanet also represents a dedicated coding system for rare diseases by a stable and unique ORPHA number [8]. Since the above terminologies cover the IRDs domain, we have incorporated them all throughout our study.

An ontology consists of concepts that organize domain knowledge with defined terms, concepts, and their relationships in a given field of study. Ontologies are useful both for providing consistent domain concepts and representing structured data formats in order to facilitate the knowledge discovery process [21]. With regards to the importance of terminological systems in the recorded history of biological and natural sciences [22], Sergouniotis et al. [8] presented a hierarchical ontology for ocular phenotypes and rare ocular diseases that covered all the rare diseases not only IRD concepts. In addition, only the entities were extracted based on the two systems of Human Phenotype Ontology and Orphanet Rare Disease Ontology and did not include the genetic concepts. While in the present study, we desired to develop a dedicated classification, specifically for IRD concepts.

One of the preliminary steps in selecting or developing a new classification or ontology system is to search for existing ones. Evaluation of the content coverage of existing (or new) ontologies is a quintessential feature of each terminological (ontological) system. Content coverage presents the extent of content representation (either term or concept) for a developed terminology, based on the standards and is highly recommended to be evaluated in order to expand the adequacy of the content representation [10, 23]. A systematic review shows that there are few studies focusing on the content coverage evaluation of terminological systems in the ophthalmology domain [10]. In the study by Hwang et al. [12], content coverage analysis was conducted on five controlled terminological systems of ICD-9, Logical Observation Identifiers, Names, and Codes (LOINC), SNOMED-CT, Medical Entities Dictionary (MED), and Current Procedural Terminology, fourth edition (CPT-4). It was concluded that the content coverage of these five evaluated systems was not perfect for general ophthalmic concepts. In another study by Chiang et al. [13], higher content coverage was found for the SNOMED-CT system for general ophthalmic concepts in comparison with ICD-9, CPT-4 and MED terminological systems.

Lack of consistent coding of IRD concepts by terminological systems may result in documenting and extracting unreliable information from electronic systems including patient registries and electronic health records (EHRs). These issues may raise the challenges of semantic interoperability among electronic systems [24]. The objective of this study was two-sided: Firstly, we developed a classification for IRD concepts, and secondly, we evaluated the content coverage of some well-known terminological systems for our proposed IRD classification to validate this classification for documentation of IRD concepts.

Results

Our proposed classification for IRD concepts

Initially, during our literature review, we created a prototype classification that contained 62 IRD-related concepts based on anatomical and functional features as well as genetic characteristics in six categories (S1 Table). Gradually, such classification was expanded to 164 IRD concepts under the six main categories, represented by standard terminologies. During expert consultation sessions, several panel group discussions, and further literature review, the consensus agreed to retract eleven concepts from the proposed classification because they were not fully representing an IRD (S2 Table). Therefore, a final list was developed that contained 158 IRD concepts in six categories based on the phenotype identifications and their corresponding genetic subtypes (n = 412). In our proposed classification, the disease categorization was organized considering both anatomical and functional IRD entities in the following six categories: 1. Diffuse photoreceptor dystrophies (n = 15), 2. Macular dystrophies (n = 22), 3. Chorioretinal dystrophies (n = 12), 4. Inner retinal and/or vitreoretinal dystrophies (n = 4), 5. Retinal dystrophies associated with systemic disease (syndromic diseases) (n = 92), and 6. Congenital & stationary retinal diseases (n = 13). For further clarification of the twenty- one IRD concepts, we classified them under our proposed categories, which are performed based on the updated anatomic, functional and genetic information, although might be different from the previous classification of the standard terminological systems (S3 Table). Our final IRD classification is registered on the BioPortal website and can be accessed via this web address https://bioportal.bioontology.org/ontologies/IRD3.

Content coverage (term and concept) analysis

We evaluated our IRD classification against 5 terminological systems that we included in our scope. In general, UMLS had the greatest coverage of 90.51% compared with other evaluated systems including SNOMED-CT (83.54%), ORDO (81.01%), OMIM (60.76%), and ICD-11 (60.13%). Overall, there were 53 IRD concepts (33.54%) that were covered by all five investigated systems. However, 2.53% of the IRD concepts in our classification were not covered by any of the standard terminologies (S4 Table; for genetic classification, see Supplementary Excel sheet labeled as Terminological System for IRDs). Table 1 summarizes the coverage analysis of the developed IRD classification based on SNOMED-CT. Our classification was completely covered based on both terminologies and concepts within SNOMED-CT regarding diseases for chorioretinal dystrophies, and inner retinal and/ or vitreoretinal dystrophies. Even though there was no match for 16.46% (n = 26) of IRD concepts in SNOMED-CT, we were able to create an equivalent for 6.96% (n = 11) of the concepts by leveraging the post-coordination function in SNOMED-CT.

Table 1. Coverage analysis of the IRD ontology based on SNOMED-CT terminological system.

IRD Concepts Categories Coverage Analysis
Term Concept
No- matched Matched No- matched Matched Partially matched*
n (%) n (%) n (%) n (%) n (%)
Diffuse Photoreceptor Dystrophies 4 (26.67) 11 (73.33) 4 (26.67) 10 (66.67) 1 (6.66)
Macular Dystrophies 4 (18.18) 18 (81.82) 4 (18.18) 17 (77.27) 1 (4.55)
Chorioretinal Dystrophy 0 (0.0) 12 (100) 0 (0.0) 9 (75.0) 3 (25.0)
Inner Retinal and/or Vitreoretinal Dystrophies 0 (0.0) 4 (100) 0 (0.0) 4 (100) 0 (0)
Retinal Dystrophies Associated with Systemic Disease (Syndromic Diseases) 16 (17.39) 76 (82.61) 16 (17.39) 72 (78.26) 4 (4.35)
Congenital & Stationary Retinal Diseases 2 (15.38) 11 (84.62) 2 (15.38) 9 (69.24) 2 (15.38)

IRD, inherited retinal dystrophy; SNOMED-CT, Systematized Nomenclature of Medicine—Clinical Terms; n, number

* Partially matched were considered as same as post coordinated terms in cases with no possibility of term matching and covering by alternative terms.

Table 2 shows content coverage for the remaining 4 terminologies (ICD-11, ORDO, OMIM, and UMLS), of our suggested IRD classification. UMLS and SNOMED-CT had the highest content coverage for all IRD categories, while the least content coverage was reported for ICD-11.

Table 2. Coverage analysis of the IRD ontology based on the terminological systems.

Coverage Analysis
IRD Concepts Categories Terminological Systems No-matched Matched
n (%) n (%)
Diffuse Photoreceptor Dystrophies ICD-11 6 (40.0) 9 (60.0)
ORDO 5 (33.33) 10 (66.67)
OMIM 5 (33.33) 10 (66.67)
UMLS 1 (6.67) 14 (93.33)
Macular Dystrophies ICD-11 9 (40.90) 13 (59.10)
ORDO 4 (18.18) 18 (81.82)
OMIM 11 (50.0) 11 (50.0)
UMLS 3 (13.64) 19 (86.36)
Chorioretinal Dystrophies ICD-11 2 (16.67) 10 (83.33)
ORDO 3 (25.0) 9 (75.0)
OMIM 5 (41.67) 7 (58.33)
UMLS 2 (20.0) 10 (80.0)
Inner Retinal and/or Vitreoretinal Dystrophies ICD-11 1 (25.0) 3 (75.0)
ORDO 0 (0) 4 (100)
OMIM 1 (25.0) 3 (75.0)
UMLS 0 (0) 4 (100)
Retinal Dystrophies Associated with Systemic Disease (Syndromic Diseases) ICD-11 41 (44.56) 51 (55.44)
ORDO 15 (16.30) 77 (83.70)
OMIM 32 (34.78) 60 (65.22)
UMLS 6 (6.52) 86 (93.48)
Congenital & Stationary Retinal Diseases ICD-11 4 (30.77) 9 (69.23)
ORDO 3 (23.07) 10 (76.93)
OMIM 8 (61.54) 5 (38.46)
UMLS 3 (23.07) 10 (76.93)

IRD, Inherited Retinal Dystrophy; ICD, International Classification of Diseases; ORDO, Orphanet Rare Disease Ontology; OMIM, Online Mendelian Inheritance in Man; UMLS, Unified Medical Language System; n, number

Discussion

This study proposes a classification for IRD concepts and terminologies. This will benefit sub-specialists in the field of IRD diseases, who are trying to go to a nomenclature system that facilitates the allocation of disorders into precise categories based on individual gene mutations, which is the result of improving diagnostic techniques. Evaluation of content coverage was based on the UMLS, ICD- 11, ORDO, OMIM and SNOMED- CT terminologies. The highest content coverage was obtained for the UMLS system due to the generalizability of this system for a variety of biomedical vocabularies [17].

One of the shortcomings of OMIM is that its concept coding is not based on a uniform pattern, hence, various IRD concepts with the same underlying gene were considered as a distinct diagnosis, while in some other cases one concept was defined as the main one and the other one was considered as an alternative term. For instance, RP14 "OMIM: # 600132" and LCA15 "OMIM: # 613843" were considered as two distinct phenotypes, although TULP1 is a single causative gene of both diagnoses. Conversely, LCA13 "OMIM: # 612712" is considered as the main term and RP53 "OMIM: # 612712" is defined as its alternative term when RDH12 is the causative gene for both phenotypes. To resolve this discrepancy, we considered a unique code for each causative gene, despite having various phenotypes, in our proposed classification. In addition, we adopted this approach in cases when a single gene was the causing factor of various IRD diagnoses. Another limitation of the OMIM terminology system is that all subtypes of each IRD concept were determined only by a single OMIM code like "Retinitis punctata albescens; # 136880", whereas, in our proposed classification, each subtype has a unique code.

Acceptable content coverage was observed in ICD-11 for non-genetic based IRD concepts; however, its accuracy needs to be further evaluated. For instance, the same code of 5C56.00 is assigned to different types of GM Ganliosidosis.

Although a high level of content coverage was obtained for UMLS Metathesaurus, it is not widely incorporated in electronic health record and data entry systems. Therefore, enhancing content coverage of the more commonly used clinical terminologies such as ICD and SNOMED-CT could facilitate a wider adoption.

There were eleven IRD diagnoses that are represented ORDO classification system; however, we decided to exclude them from our proposed classification. IRD concepts that were removed from our classification, together with a brief description of the reason, are as follow:

  1. Albers-Schönberg Osteopetrosis

    This entity is classified as genetic macular dystrophy in ORDO system [25], while blindness, optic atrophy and visual loss are only the main ophthalmic complications reported by different studies cited by OMIM system [2629]. This concept is categorized as a type of "hereditary disorder of the musculoskeletal system" by SNOMED-CT and ICD-11 considered it as a subtype of osteopetrosis diagnosis [30].

  2. Foveal Hypoplasia—Presenile Cataract Syndrome

    This concept is classified as IRD by ORDO without additional explanation [31]. UMLS provides a CUI with no explanation, while it is not represented in SNOMED-CT. It is classified as a subtype of "other cataract" related to "Infantile and juvenile cataract" classification. Based on OMIM results, it is an ocular disease which is presented with aniridia.

  3. Hermansky—Pudlak Syndrome with Neutropenia

    SNOMED-CT does not consider this concept as IRD and classifies it as a metabolic disorder by ICD- 11 as well [32]. A CUI code is assigned for this concept by UMLS system with no additional explanation. In ORDO and OMIM, oculocutaneous albinism is a known ocular finding in these patients [33].

  4. Leigh Syndrome

    This disease is manifested by involvement of the central nervous system (CNS) resulting in ophthalmoplegia as a common ocular finding. OMIM considers it as a disorder of the CNS with no relation to any specific ocular disease [34]. Vision loss and eye movement abnormality are the common ocular findings, as shown in UMLS. Both SNOMED-CT and ICD- 11 considered this diagnosis as a hereditary disorder of the CNS, as well [35].

  5. Metachromatic Leukodystrophy

    ICD- 11 system considered it as a subtype of metabolic disease [36], but UMLS and SNOMED-CT consider it as a hereditary disorder of the nervous system with no ocular manifestation. OMIM system reports no ocular finding [37].

  6. Rubinstein—Taybi Syndrome

    It is considered as congenital glaucoma by OMIM system [38]. Glaucoma, refractive error and nasolacrimal duct obstruction are common ocular findings reported by ORDO system [39]. SNOMED-CT classifies this concept as hereditary cancer predisposing syndrome. No ocular findings were reported by UMLS system. ICD- 11 also considers it as a congenital anomaly [40].

  7. Retinal Vasculopathy with Cerebral Leukoencephalopathy and Systemic Manifestations

    SNOMED-CT does not specify any code for this diagnosis, while UMLS has a CUI for it with no definition. Hereditary vascular retinopathy, hereditary endotheliopathy with retinopathy as well as progressive visual impairment are all represented as ocular manifestations in ORDO [41].

  8. Revesz syndrome

    This concept is classified as IRD by ORDO with ocular manifestation of bilateral exudative retinopathy [42]. The same definition exists in UMLS. This concept is also covered by OMIM, without any relationship to retinal dystrophies [43]. This concept is classified as a subtype of hereditary disorder of the visual system by SNOMED-CT.

  9. Aceruloplasminemia

    This clinical diagnosis is classified as IRD by UMLS, while it is considered a metabolic disease by SNOMED-CT.

  10. Cockayne Syndrome

    Photosensitivity is only the visual finding which is included in ORDO [44]. Additionally, the common ocular manifestations represented in UMLS are photosensitivity, vision impairment, and retinal pigmentation. Congenital cataract is a single ocular finding reported by OMIM, while ICD- 11 emphasizes on congenital malformation in the affected individuals [45]. SNOMED-CT considers it a subtype of hereditary disorder of the nervous system.

  11. Xeroderma Pigmentosum—Cockayn Syndrome Complex

    There is no concept code for this diagnosis in UMLS or SNOMED-CT. ORDO classifies it as IRD [46], while ICD- 11 only emphasizes on congenital malformation [47]. There is no finding suggestive of retinal dystrophy presented by OMIM.

Although the proposed classification is the first dedicated hierarchy for subtypes of IRD diagnoses, a suitable linkage to standard terminologies is highly recommended which would be of importance for standardization, maintenance, and reusability of this classification.

The primary purpose of the present study is to present a classification for IRDs and we intend to continue our study focusing on the comparison of our classification system with concepts identified in literature by Natural Language Processing (NLP) algorithms and implementing of this classification in the form of an interface terminology and evaluating user perspectives in terms of usability and clinical applications. Additionally, generation of a mapping between IRD concepts and the target terminologies was a side benefit of our study. Considering the fact that such IRD concepts are inherited via genetic mutations, coding IRD concepts with regards to their genetic mutations is highly desirable.

Although there is no definite cure for IRDs at present, accurate diagnosis and identification of the causative gene mutations can facilitate the creation of animal models for providing gene therapy for IRDs. Therefore, any classification system like ontologies or reference terminologies would become essential tools for personalized medicine specific to IRD diseases and facilitate the description and specification of complex IRD concepts based on the genotype-phenotype distinction.

Considering functional and anatomical attributes, within seven categories, in our IRD classification is the most prominent factor in the proposed classification, which would certainly be helpful in designing future studies focusing on each IRD subtype.

Considering the fact that the World Health Organization (WHO) has already developed the ICD-11 Ophthalmology Specialty Linearization, the proposed classification can be considered a hierarchical prototype for the particular type of ophthalmic diseases.

In conclusion, the specialized classification system that we created, including terms and concepts, is dedicated to various types of IRD diagnosis and has the potential to be applied in the clinics and electronic information systems. More importantly, it may be considered as a preliminary step toward development of a standard ontology for inherited retinal diseases. In addition, the study indicates that many of available terminology systems has little coverage of IRD concepts and only UMLS covers more than 90 percent of concepts. Therefore, our classification system can also be applied to develop and update further versions of standard classification systems.

Methods

In our proposed classification system, each IRD disease is mainly grouped based on the main origin of its pathological problem considering both anatomical and functional concepts. Three steps were taken in our study to develop IRD classification and evaluate the content coverage of terminological systems regarding the IRD concepts.

Step I: Development of a classification for IRD concepts

Initially, a working group of two academic, board-certified retina specialists, one academic molecular geneticist, and five medical informatics specialists was organized. Then, a comprehensive literature review on IRDs was conducted including the textbooks [4850], and original and review articles [5, 5180] in order to develop a primary classification based on the anatomical, functional, and pathological concepts related to IRDs. Afterwards, a comprehensive search was conducted up to December 2022 on five terminological systems, including UMLS, ICD-11, SNOMED-CT, ORDO and OMIM to look for any existing terminology for different genetic and phenotypic IRDs to be added accordingly to our primary classification. Then, a questionnaire was developed based on the identified diagnoses, where it was discussed with an expert panel of nine academic board-certified retina specialists regarding the scientific and conceptual accuracy of each IRD concept. Ten expert panel discussion sessions with an interval of one month were held in order to collect all comments and feedback. In each session, 40 IRD concepts were reviewed. After this phase, some irrelevant or duplicated IRD concepts were dropped from the classification list and some concepts were classified in the updated categories based on their functional and anatomical characteristics. All participants were asked to provide "yes", "no" or “maybe” response to “validated”, “not validated”, and “suspected” concepts, respectively. IRD concepts that were labelled as "maybe" were discussed in the subsequent sessions of the expert panel to yield confirmation. This process continued until reaching a final decision. The concepts labeled as “yes” with an agreement of 70% or more were considered as IRD concept, otherwise they were defined as “not validated” IRD concept. To obtain a comprehensive consensus, the summary of the results of the previous sessions was presented in the succeeding meetings. Eventually, after applying the proposed changes to the classification it was finalized based on the consensus of the panel group members based on the workflow represented in Fig 1. Finally, an organized hierarchy of IRD concepts was developed in an ontology editor platform called Protégé (Fig 2). This proposed classification was structured based on the phenotype characteristics and the genetic concepts were included to the related IRD diagnosis.

Fig 1. Our workflow to develop the proposed classification.

Fig 1

IRD, inherited retinal dystrophy. 1 Presented on Supplementary data, Table 1. 2 Presented on Supplementary data, Table 2. 3 Developed by Protégé software and it could be accessible on BioPortal website through the URL address of http://bioportal.bioontology.org/ontologies/IRD3.

Fig 2. A screenshot of registered inherited retinal dystrophy concepts in Protégé software.

Fig 2

Step II: Extraction of annotation for each IRD concept

In this phase, all annotations for each IRD concept including code, fully specified name, synonyms (alternative descriptions) in other terminological systems were extracted by two experts: a vision scientist and a medical informatics specialist. This information was documented in a separate datasheet for further comparison. We also assigned a unique internal code for each IRD concept in order to create a mapping network for future data integration.

Step III: Comparison among terminological systems for content coverage analysis

Content coverage analysis was conducted from two aspects; terms and concepts [81]. As previously stated, term- and concept- coverage are considered as the extent of term and concept representation of our proposed classification based on the five mentioned terminological systems.

Initially, each IRD concept in our classification was checked against terminological systems in order to find the relevant or equivalent terms and/or concepts. We classified our results as "no match", "partial match" or "complete match". An IRD concept was considered as term- and concept- matched if the term was completely representable throughout the above-mentioned terminological systems. Further evaluation regarding concept matching was performed for no-term-matched IRD contents. "Complete concept match" was defined in cases where alternative terms (or synonymous) existed. In SNOMED-CT, we considered post-coordination if no synonym was found. In fact, if it was possible to develop a concept with post-coordination, we considered that concept as “partial match”. IRD contents with no possibility of post-coordination were considered as “complete no match”. The percentage for each of the above- mentioned conditions was reported by the terminological systems. Our content coverage approach is illustrated in Fig 3. An example of the content coverage analysis of IRD concepts based on the SNOMED- CT system is shown in Fig 4.

Fig 3. Our workflow to evaluate the content coverage of the proposed classification based on the standard terminological systems.

Fig 3

Fig 4. Representation of examples for different levels of term- and concept- matching for inherited retinal dystrophy (IRD) concepts based on SNOMED-CT.

Fig 4

Declarations

Ethics approval and consent to participate

The study details were presented to the Ethics Committee of the Ophthalmic Research Center affiliated to Shahid Beheshti University of Medical Sciences and approved via the registration number of IR.SBMU.ORC.REC.1396.15. This article does not contain any studies with human participants or animals performed by any of the authors, therefore the informed consent was waived based on the local Research Ethics Committee decision.

Supporting information

S1 File. All terminological systems and causative gene.

(XLSX)

S1 Table. A preliminary classification of inherited retinal dystrophy (IRD) concepts.

(DOCX)

S2 Table. Not validated concepts as inherited retinal dystrophy (IRD).

(DOCX)

S3 Table. Classification of IRD concepts in our proposed ontology and applied standard terminological system.

(DOCX)

S4 Table. A list of IRD concepts coded by all systems and those coded by none of systems.

(DOCX)

Acknowledgments

The authors desire to express their deep gratitude to the research subcommittee of the Iranian National Registry for Inherited Retinal Diseases (IRDReg®).

Data Availability

Additional data has been uploaded to the journal website as Supporting Information files.

Funding Statement

The authors received no specific funding for this work.

References

Decision Letter 0

Alfred S Lewin

18 Jul 2022

PONE-D-22-12220A Health Terminological System for Inherited Retinal Diseases: Content Coverage Evaluation and a Proposed Novel ClassificationPLOS ONE

Dear Dr. sheikhtaheri,

Thank you for submitting your manuscript to PLOS ONE.  After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. I am sorry that it has taken a long time to present you with a review, but we were trying to find a second expert to review your submission.  In the interests of time, I decided to ask for revision based on the comments of one expert whose comments are valuable.

Please modify your comments about the novelty of your work, because there are already several classification systems for IRDs, though none is widely accepted. Please explain how genetic data informed your classification scheme.  The reviewer indicates that including genotypic information is important.

Please submit your revised manuscript by Sep 01 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Alfred S Lewin, Ph.D.

Section Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf  and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following financial disclosure:

“The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

At this time, please address the following queries:

a)        Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.

b)        State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

c)        If any authors received a salary from any of your funders, please state which authors and which funders.

d)        If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

3. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors present a novel IRD classification. The methodology used to achieve this new classification is well defined and all data was made available. Please find my queries below:

Abstract

– Purpose: Please use “To present a novel…” instead of “To represent a novel…”

Introduction

– The authors write: “to the best of our knowledge there is no dedicated ontology or classification for IRD concepts”. This is not true. There are several proposed classifications. However, I would say there is not one widely accepted classification. Also, please check PMID: 30626441 (ref 8 in your references list). The authors present a summary of the modifications made to HPO and ORDO as part of the study (Table S1), and list the disease groups and specific disorders introduced to ORDO as a result of the ERN-EYE Ontology meeting (Mont Sainte-Odile, France, 10/2017). The ERN-EYE is an European Reference Network covering all rare eye disorders and not only IRDs. The group has worked hand in hand with ORPHANET to improve IRD and other rare eye disease nomenclature in ORDO.

– Please replace “…to validate the value of this novel…” for “…to validate this novel…”

Methods

– Step I: the authors write “This proposed classification was structured based on the phenotype characteristics and the genetic concepts were included to the related IRD diagnosis.” Please elaborate on the genetic concepts. I cannot find in the text, tables, figures or supplemental material any reference to the genetic cause of the proposed diagnoses. In fact, I would say the major issue with the presented classification is that it lacks genetic information. Please elaborate on this as it is a fundamental part of any new IRD classification. Several genes are able to cause different phenotypes and gene-based classifications are getting more popular. Developing a strong phenotypical classification is important but it must incorporate genetic data, ie, genes associated with each phenotype and must allow seeing things the other way around, ie which phenotypes are associated with each gene.

– Another issue is that some diagnoses fit more than one category. An example would be central areolar choroidal dystrophy (CACD) which fits the macular dystrophies group and choroidal dystrophies group. The same is true for syndromic forms of retinitis pigmentosa (eg Usher, BBS) that fit the Retinal dystrophies associated with systemic disease (syndromic diseases) group and the Diffuse Photoreceptor Dystrophies group; or syndromic forms of cone-rod dystrophy (eg. Cone-rod dystrophy and hearing loss, caused by CEP250 mutations) that fit the Retinal dystrophies associated with systemic disease (syndromic diseases) group Diffuse Photoreceptor Dystrophies group. Please comment.

– What about cases where the phenotype changes or does not fit any of the proposed groups? Some PRPH2-associated macular dystrophies for instance. Shouldn’t there be a group for cases that cannot be classified anywhere else?

Supplementary table 1

– Is the term “regional retinitis pigmentosa” a synonym of “sector retinitis pigmentosa”? If yes, than the term sector retinitis pigmentosa should be used instead, as this is the most common term

References

– Duplicate references! Ref 8 and ref 21 are the same

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Aug 4;18(8):e0281858. doi: 10.1371/journal.pone.0281858.r002

Author response to Decision Letter 0


13 Oct 2022

PONE-D-22-12220

A Health Terminological System for Inherited Retinal Diseases: Content Coverage Evaluation and a Proposed Novel Classification

PLOS ONE

Dear Dr. Sheikhtaheri,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. I am sorry that it has taken a long time to present you with a review, but we were trying to find a second expert to review your submission. In the interests of time, I decided to ask for revision based on the comments of one expert whose comments are valuable.

Please submit your revised manuscript by Sep 01 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

• A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

• A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

• An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Alfred S Lewin, Ph.D.

Section Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following financial disclosure:

“The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

At this time, please address the following queries:

a) Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.

b) State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

c) If any authors received a salary from any of your funders, please state which authors and which funders.

d) If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

3. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

[Note: HTML markup is below. Please do not edit.]

Editor comment

Please modify your comments about the novelty of your work, because there are already several classification systems for IRDs, though none is widely accepted. Please explain how genetic data informed your classification scheme. The reviewer indicates that including genotypic information is important.

Answer: The IRD hierarchy has been revised based on both genetic and anatomical entities. Also, all required modifications have been performed throughout the text. Although there are several classification systems for rare eye diseases, no certain hierarchy has been developed specifically for IRD concepts. The current IRD classification has been developed based on the textbooks review, and the related standard terminologies such as Unified Medical Language System (UMLS), Online Mendelian Inheritance in Man (OMIM), International Classification of Diseases (ICD-11), Systematized Nomenclature of Medicine (SNOMED-CT) and Orphanet Rare Disease Ontology (ORDO) which is more comprehensive compared with other classifications.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Answer: The conclusion part has been revised to be completely in line with the study findings.

________________________________________

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

________________________________________

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

________________________________________

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

________________________________________

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors present a novel IRD classification. The methodology used to achieve this new classification is well defined and all data was made available. Please find my queries below:

Abstract

– Purpose: Please use “To present a novel…” instead of “To represent a novel…”

Answer: It has been done.

Introduction

– The authors write: “to the best of our knowledge there is no dedicated ontology or classification for IRD concepts”. This is not true. There are several proposed classifications. However, I would say there is not one widely accepted classification. Also, please check PMID: 30626441 (ref 8 in your references list). The authors present a summary of the modifications made to HPO and ORDO as part of the study (Table S1), and list the disease groups and specific disorders introduced to ORDO as a result of the ERN-EYE Ontology meeting (Mont Sainte-Odile, France, 10/2017). The ERN-EYE is an European Reference Network covering all rare eye disorders and not only IRDs. The group has worked hand in hand with ORPHANET to improve IRD and other rare eye disease nomenclature in ORDO.

Answer: Although there are several classification systems for rare eye diseases, no certain hierarchy has been developed specifically for IRD concepts. The current IRD classification has been developed based on the text books review, and the related standard terminologies such as Unified Medical Language System (UMLS), Online Mendelian Inheritance in Man (OMIM), International Classification of Diseases (ICD-11), Systematized Nomenclature of Medicine (SNOMED-CT) and Orphanet Rare Disease Ontology (ORDO) which is more comprehensive compared with other classifications.

– Please replace “…to validate the value of this novel…” for “…to validate this novel…”

Answer: It has been done.

Methods

– Step I: the authors write “This proposed classification was structured based on the phenotype characteristics and the genetic concepts were included to the related IRD diagnosis.” Please elaborate on the genetic concepts. I cannot find in the text, tables, figures or supplemental material any reference to the genetic cause of the proposed diagnoses. In fact, I would say the major issue with the presented classification is that it lacks genetic information. Please elaborate on this as it is a fundamental part of any new IRD classification. Several genes are able to cause different phenotypes and gene-based classifications are getting more popular. Developing a strong phenotypical classification is important but it must incorporate genetic data, ie, genes associated with each phenotype and must allow seeing things the other way around, ie which phenotypes are associated with each gene.

Answer: The IRD hierarchy has been revised based on both genetic and anatomical entities. Also, all required modifications have been performed throughout the text.

– Another issue is that some diagnoses fit more than one category. An example would be central areolar choroidal dystrophy (CACD) which fits the macular dystrophies group and choroidal dystrophies group. The same is true for syndromic forms of retinitis pigmentosa (eg Usher, BBS) that fit the Retinal dystrophies associated with systemic disease (syndromic diseases) group and the Diffuse Photoreceptor Dystrophies group; or syndromic forms of cone-rod dystrophy (eg. Cone-rod dystrophy and hearing loss, caused by CEP250 mutations) that fit the Retinal dystrophies associated with systemic disease (syndromic diseases) group Diffuse Photoreceptor Dystrophies group. Please comment.

Answer: Thank you for raising this concern, which is a potential issue in any classification system. In our proposed classification system, each IRD disease is mainly grouped based on the main origin of its pathological problem considering both anatomical and functional concepts. Although, many IRDs gradually progress and after a while will involve other adjacent structures. For instance, as you indicated CACD is mostly a choroidal disease that gradually extends to involve the macular region or farther parts of the retina. Therefore, in our classification system, we grouped this diagnosis under choroidal dystrophies. In the same way, we classified the “diffuse photoreceptor dystrophies” as a group containing the IRDs that exclusively involve the retina with no other organ involvement, besides there is another group of “systemic diseases associated with photoreceptor dystrophies” to embrace retinal dystrophies that have an associated systemic or organ condition such as BBS and Usher syndrome or cone-rod dystrophy and hearing loss. Please refer to supplementary table 1.

– What about cases where the phenotype changes or does not fit any of the proposed groups? Some PRPH2-associated macular dystrophies for instance. Shouldn’t there be a group for cases that cannot be classified anywhere else?

Answer: You have pointed out a great example. We reported a complex family affected with different clinical features of inherited retinal dystrophy, including fundus flavimaculatus as an early clinical feature progressing to extensive chorioretinal atrophy involving the macula and mid-periphery of the fundus in one parent and central areolar chorioretinal dystrophy (CACD) as the most probable clinical diagnosis in another parent. Macular pattern dystrophy for one of their daughters and a Leber congenital amaurosis (LCA) like phenotype for the daughter with an early onset retinal dystrophy (EORD) phenotype. (Daftarian N, et al. Ophthalmic Genetics, 40:5, 436-442). Therefore, in our proposed classification, the disease categorization was organized considering both anatomical and functional IRD entities in seven groups, instead of being exclusively based on the genetic, anatomic or functional diagnosis. Supplementary table 1

– Is the term “regional retinitis pigmentosa” a synonym of “sector retinitis pigmentosa”? If yes, then the term sector retinitis pigmentosa should be used instead, as this is the most common term.

Answer: Thank you for alluding to another precise point. We replaced it with the more familiar term “sector retinitis pigmentosa” and then will use the regional retinitis pigmentosa as the alternative one.

References

– Duplicate references! Ref 8 and ref 21 are the same.

Answer: Many thanks, the list of references has been revised.

________________________________________

6. PLOS authors have the option to publish the peer review history of their article. If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Alfred S Lewin

1 Nov 2022

PONE-D-22-12220R1A Health Terminological System for Inherited Retinal Diseases: Content Coverage Evaluation and a Proposed ClassificationPLOS ONE

Dear Dr. sheikhtaheri,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please provide a table in which the genes associated with each proposed diagnosis are shown. Your final classification system should contain both anatomical and genetic classifications.

Please submit your revised manuscript by Dec 16 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Alfred S Lewin, Ph.D.

Section Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Thank you for your revision. You have addressed most of my concerns. However, one major issue remains:

I still cannot find any table or supplemental table where the genes associated with each proposed diagnosis are shown. The link you provide with your final classification (https://bioportal.bioontology.org/ontologies/IRD1) separates the genetic classification (genetic_variantion) from the anatomical classification (Inherited_retinal_Dystrophy). It is my understanding that a novel classification should merge botth.

Let’s see a practical example: retinitis pigmentosa associated with biallelic EYS variants:

According to your proposed classification system, this would be:

IRD_1_1 but there are several causative genes so we should be able to select the causative gene (IRD_1_1#21 according to your genetic variation list) from the first classification.

Please provide a merged classification.

Minor issues

- Why do you separate AR and AD pericentral pigmentary retinopathy? I understand the same phenotype may be caused by AR or AD genes but if you are separating it here according to the inheritance pattern, then you should be doing the same for Retinitis Pigmentosa (AR, AD, XL), Cone-rod dystrophy (AR, AD, XL), etc

- Wouldn’t it be easier to join Choroidal dystrophies (IRD 3) with Chorioretinal dystrophies (IRD 7)?

- Regarding the "Supporting Information – Final Classification and Coverage Version 12.18.2021", the authors did not change the term “regional” to “sector” retinitis pigmentosa

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Aug 4;18(8):e0281858. doi: 10.1371/journal.pone.0281858.r004

Author response to Decision Letter 1


1 Feb 2023

PONE-D-22-12220R1

A Health Terminological System for Inherited Retinal Diseases: Content Coverage Evaluation and a Proposed Classification

PLOS ONE

Editor comment

Please provide a table in which the genes associated with each proposed diagnosis are shown. Your final classification system should contain both anatomical and genetic classifications.

Thank you for the comment. We added genes information.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

________________________________________

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Answer: The conclusion part has been revised to be more corresponding with our findings.

________________________________________

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

________________________________________

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

________________________________________

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

________________________________________

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Thank you for your revision. You have addressed most of my concerns. However, one major issue remains:

I still cannot find any table or supplemental table where the genes associated with each proposed diagnosis are shown. The link you provide with your final classification (https://bioportal.bioontology.org/ontologies/IRD1) separates the genetic classification (genetic_variantion) from the anatomical classification (Inherited_retinal_Dystrophy). It is my understanding that a novel classification should merge both.

Let’s see a practical example: retinitis pigmentosa associated with biallelic EYS variants:

According to your proposed classification system, this would be:

IRD_1_1 but there are several causative genes so we should be able to select the causative gene (IRD_1_1#21 according to your genetic variation list) from the first classification.

Please provide a merged classification.

Answer: The merged IRDs hierarchy combining both anatomical and genetic codes providing based on five standard coding systems has been submitted to the website as well as the BioPortal website.

Minor issues

- Why do you separate AR and AD pericentral pigmentary retinopathy? I understand the same phenotype may be caused by AR or AD genes but if you are separating it here according to the inheritance pattern, then you should be doing the same for Retinitis Pigmentosa (AR, AD, XL), Cone-rod dystrophy (AR, AD, XL), etc.

Answer: The title of each IRD entity either includes the inheritance pattern or not has been selected based on the standard terminologies without any updates and no suggested terms have been inserted into the heicharcy.

- Wouldn’t it be easier to join Choroidal dystrophies (IRD 3) with Chorioretinal dystrophies (IRD 7)?

Answer: These two categories have been merged into the one group labeled as "Choroidal Dystrophy".

- Regarding the "Supporting Information – Final Classification and Coverage Version 12.18.2021", the authors did not change the term “regional” to “sector” retinitis pigmentosa.

Answer: It has been changed as you recommended.

________________________________________

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

________________________________________

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 2

Alfred S Lewin

3 Feb 2023

A Health Terminological System for Inherited Retinal Diseases: Content Coverage Evaluation and a Proposed Classification

PONE-D-22-12220R2

Dear Dr. sheikhtaheri,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Alfred S Lewin, Ph.D.

Section Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Alfred S Lewin

7 Feb 2023

PONE-D-22-12220R2

A Health Terminological System for Inherited Retinal Diseases: Content Coverage Evaluation and a Proposed Classification

Dear Dr. Sheikhtaheri:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Alfred S Lewin

Section Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. All terminological systems and causative gene.

    (XLSX)

    S1 Table. A preliminary classification of inherited retinal dystrophy (IRD) concepts.

    (DOCX)

    S2 Table. Not validated concepts as inherited retinal dystrophy (IRD).

    (DOCX)

    S3 Table. Classification of IRD concepts in our proposed ontology and applied standard terminological system.

    (DOCX)

    S4 Table. A list of IRD concepts coded by all systems and those coded by none of systems.

    (DOCX)

    Attachment

    Submitted filename: Response to Reviewers.docx

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    Additional data has been uploaded to the journal website as Supporting Information files.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES